Giles Platford on Takeda’s 5 Year Deal with WFH for The Humanitarian Aid Program!
Giles Platford, President, Plasma-Derived Therapies Business Unit at Takeda and Chair of the Global Executive Board at PPTA, reposted from World Federation of Hemophilia on LinkedIn:
”I’m proud to share this important milestone: Takeda has renewed its 5-year agreement with the WFH and WFH_USA—furthering our support for the WFH Humanitarian Aid Program!
Together with other partners, we are working to expand access, drive equity, and change lives for people living with inherited bleeding disorders globally.”
Quoting World Federation of Hemophilia‘s post:
”The WFH and WFH USA are pleased to announce that Takeda has signed a 5-year agreement renewal with the WFH Humanitarian Aid Program from 2026 to 2030!
The agreement is for the donation of treatment product, as well as a financial commitment to cover it’s handling, storage and shipping. Learn more.”
Stay updated with Hemostasis Today.
-
Apr 30, 2026, 13:01William Aird: When Inducers Make DOACs Fail
-
Apr 30, 2026, 12:56Abdul Muqtadir Abbasi: HIT Management – Avoid Platelet Transfusion
-
Apr 30, 2026, 12:45Chokri Ben Lamine: Methemoglobinemia in Hematology – Causes, Diagnosis, Antidote
-
Apr 30, 2026, 08:11Navya Sree: Breaking Down DVT From Theory to Practice
-
Apr 30, 2026, 06:06Shashank Joshi: The Emerging Role of Inflammatory Biomarkers in Acute CVS Thrombosis
-
Apr 30, 2026, 05:30John Bramble: Ensuring Safe AI Integration in Medicine
-
Apr 30, 2026, 04:55Danielle Stull: Raising Awareness of CVS Thrombosis in Young Women
-
Apr 29, 2026, 17:25Robert Brodsky: Ravulizumab Appears To Be Safe And Effective In Pregnancy
-
Apr 29, 2026, 16:53Chokri Ben Lamine: IV Iron Showdown – FCM vs Ferric Derisomaltose vs Iron Dextran